Exosome-based immunotherapy: a promising approach for cancer treatment
- PMID: 33183286
- PMCID: PMC7661275
- DOI: 10.1186/s12943-020-01278-3
Exosome-based immunotherapy: a promising approach for cancer treatment
Abstract
In the era of the rapid development of cancer immunotherapy, there is a high level of interest in the application of cell-released small vesicles that stimulate the immune system. As cell-derived nanovesicles, exosomes show great promise in cancer immunotherapy because of their immunogenicity and molecular transfer function. The cargoes carried on exosomes have been recently identified with improved technological advances and play functional roles in the regulation of immune responses. In particular, exosomes derived from tumor cells and immune cells exhibit unique composition profiles that are directly involved in anticancer immunotherapy. More importantly, exosomes can deliver their cargoes to targeted cells and thus influence the phenotype and immune-regulation functions of targeted cells. Accumulating evidence over the last decade has further revealed that exosomes can participate in multiple cellular processes contributing to cancer development and therapeutic effects, showing the dual characteristics of promoting and suppressing cancer. The potential of exosomes in the field of cancer immunotherapy is huge, and exosomes may become the most effective cancer vaccines, as well as targeted antigen/drug carriers. Understanding how exosomes can be utilized in immune therapy is important for controlling cancer progression; additionally, exosomes have implications for diagnostics and the development of novel therapeutic strategies. This review discusses the role of exosomes in immunotherapy as carriers to stimulate an anti-cancer immune response and as predictive markers for immune activation; furthermore, it summarizes the mechanism and clinical application prospects of exosome-based immunotherapy in human cancer.
Keywords: Cancer immunotherapy; Cancer vaccines; Clinical implications; Exosomes; Immune cells.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


Similar articles
-
Exosomes as carriers to stimulate an anti-cancer immune response in immunotherapy and as predictive markers.Biochem Pharmacol. 2025 Feb;232:116699. doi: 10.1016/j.bcp.2024.116699. Epub 2024 Dec 6. Biochem Pharmacol. 2025. PMID: 39647605 Review.
-
Exosome-based anticancer vaccines: From Bench to bedside.Cancer Lett. 2024 Jul 28;595:216989. doi: 10.1016/j.canlet.2024.216989. Epub 2024 May 31. Cancer Lett. 2024. PMID: 38825162 Review.
-
How can nanotechnology help membrane vesicle-based cancer immunotherapy development?Hum Vaccin Immunother. 2013 Jan;9(1):222-5. doi: 10.4161/hv.22130. Epub 2012 Oct 29. Hum Vaccin Immunother. 2013. PMID: 23108359 Free PMC article.
-
The multifaceted role of exosomes in cancer progression: diagnostic and therapeutic implications [corrected].Cell Oncol (Dordr). 2018 Jun;41(3):223-252. doi: 10.1007/s13402-018-0378-4. Epub 2018 Apr 17. Cell Oncol (Dordr). 2018. PMID: 29667069 Review.
-
Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.AAPS J. 2021 Feb 14;23(2):30. doi: 10.1208/s12248-021-00554-4. AAPS J. 2021. PMID: 33586060 Free PMC article. Review.
Cited by
-
The role of exosomes in liver cancer: comprehensive insights from biological function to therapeutic applications.Front Immunol. 2024 Oct 21;15:1473030. doi: 10.3389/fimmu.2024.1473030. eCollection 2024. Front Immunol. 2024. PMID: 39497820 Free PMC article. Review.
-
Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development.Med Sci (Basel). 2024 Aug 28;12(3):43. doi: 10.3390/medsci12030043. Med Sci (Basel). 2024. PMID: 39311156 Free PMC article. Review.
-
Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy.Cancers (Basel). 2022 Oct 19;14(20):5121. doi: 10.3390/cancers14205121. Cancers (Basel). 2022. PMID: 36291904 Free PMC article. Review.
-
Exploring the roles and molecular mechanisms of RNA binding proteins in the sorting of noncoding RNAs into exosomes during tumor progression.J Adv Res. 2024 Nov;65:105-123. doi: 10.1016/j.jare.2023.11.029. Epub 2023 Nov 27. J Adv Res. 2024. PMID: 38030125 Free PMC article. Review.
-
Engineered exosomes as a prospective therapy for diabetic foot ulcers.Burns Trauma. 2024 Jul 18;12:tkae023. doi: 10.1093/burnst/tkae023. eCollection 2024. Burns Trauma. 2024. PMID: 39026930 Free PMC article. Review.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Csiszar A, Balasubramanian P, Tarantini S, Yabluchanskiy A, Zhang XA, Springo Z, Benbrook D, Sonntag WE, Ungvari Z. Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. Geroscience. 2019;41:209–227. doi: 10.1007/s11357-019-00064-4. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials